Wallace A. Bourgeois

Hematology | Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.

Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.

Journal: Science (New York, N.Y.)
Published: July 09, 2026

Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.

Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.

Journal: Cell
Published: July 01, 2025

CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials.

CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials.

Journal: Nature communications
Published: March 28, 2025

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Journal: Blood advances
Published: February 12, 2025

Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Journal: Blood advances
Published: February 12, 2025

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia.

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia.

Journal: bioRxiv : the preprint server for biology
Published: December 23, 2024

Epigenetic Therapies.

Epigenetic Therapies.

Journal: Cold Spring Harbor perspectives in medicine
Published: December 18, 2024

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia.

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia.

Journal: Cancer discovery
Published: October 22, 2024

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.

Journal: Leukemia
Published: June 04, 2024

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer.

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer.

Journal: Cell reports. Medicine
Published: May 15, 2024

Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative.

Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative.

Journal: Pediatric quality & safety
Published: April 19, 2024

Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia.

Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia.

Journal: Pediatric blood & cancer
Published: January 23, 2024
Showing 1-12 of 23

Last Updated: 09/26/2026